Major Focus on New Oncology Technology in Wall Str...
Traditional chemotherapy involves generally broad spectrum cytotoxic agents that kill a host of rapidly dividing cells which, while killing the rapidly growing tumor, leads to unwanted side effects such as hair loss, etc. To regain access to this targeted therapy, Genentech entered into an $860 million deal with Seattle Genetics. The company will have a total of five Phase II trials ongoing for this lead compound,...